Creative Medical Technology Holdings(股票代码:CELZ)近日宣布一项重要专利进展,旨在进一步巩固其针对1型糖尿病的Myelocelz平台的知识产权保护体系。此举标志着该公司在细胞治疗领域的战略布局迈出关键一步,为潜在疗法构筑更坚实的法律屏障。
Creative Medical Technology Holdings(股票代码:CELZ)近日宣布一项重要专利进展,旨在进一步巩固其针对1型糖尿病的Myelocelz平台的知识产权保护体系。此举标志着该公司在细胞治疗领域的战略布局迈出关键一步,为潜在疗法构筑更坚实的法律屏障。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.